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Abstract
Objective—Model systems which rapidly identify tissue drug concentrations protective of HIV 
infection could streamline the development of chemoprevention strategies. Tissue models are 
promising, but limited concentration targets exist, and no systematic comparison to cell models or 
clinical studies has been performed.
Design—We explored efficacy of maraviroc (MVC) and tenofovir (TFV) for HIV prevention by 
comparing Emax models from TZM-bl cells to vaginal tissue explants, and evaluated their 
predictive capabilities with a dose-challenge clinical study.
Methods—HIV-1JR-CSF was utilized for viral challenge. Drug efficacy was assessed using a 
luciferase reporter assay in TZM-bl cells and real-time PCR to quantify spliced RNA in a tissue 
explant model. Cell and tissue concentrations of MVC, TFV, and the active metabolite tenofovir 
diphosphate (TFVdp) were measured by LC-MS/MS and used to create Emax models of efficacy. 
Efficacy after a single oral dose of 600 mg MVC and 600 mg tenofovir disoproxil fumarate was 
predicted from cell and tissue models, and confirmed in a clinical study with viral biopsy 
challenge post-dose.
Results—TFV was >10 fold, and MVC >1000 fold, more potent in TZM-bl cells compared to 
vaginal explant tissue. In the dose-challenge study, tissues from 3/6 women were protected from 
HIV infection, which was 49% lower than predicted by TZM-bl data and 36% higher than 
predicted by tissue explant data.
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Conclusion—Comparator effective concentration data were generated for TFV and MVC in 
three HIV chemoprophylaxis models. These results provide a framework for future early 
investigations of antiretroviral efficacy in HIV prevention to optimize dosing strategies in clinical 
investigations.
Keywords
Antiretroviral therapy; prevention of sexual transmission; women; reverse transcriptase inhibitors; 
tenofovir diphosphate
Introduction
Interventions to prevent the sexual transmission of HIV are critical to curb the global HIV 
epidemic [1]. Antiretroviral agents can be used as chemoprophylaxis either systemically or 
topically to protect individuals at a high risk of HIV exposure. The first study to demonstrate 
antiretroviral efficacy was CAPRISA 004, in which coitally-dependent dosing of 1% 
tenofovir (TFV) gel reduced HIV acquisition by 39% [2]. Clinical trials including iPrEX, 
Partners PrEP, and TDF2 evaluated daily oral tenofovir disoproxil fumarate (TDF) taken 
alone or in combination with emtricitabine (FTC) in men who have sex with men (MSM), 
transgender women, and heterosexual men and women [3-5], respectively. The results were 
variable (44-73% efficacy) but provided proof-of-concept that oral antiretrovirals can 
protect against HIV transmission. However, two additional studies conducted exclusively in 
women (FemPrEP, using daily oral TDF+FTC and VOICE using either TFV 1% gel, oral 
TDF, or oral TDF+FTC) were either stopped early for futility or were unable to demonstrate 
a significant protective effect [6, 7]. This has been attributed to both differential distribution 
of antiretrovirals in mucosal tissues and poor adherence to a daily regimen.
Successful chemoprevention interventions will require the design of drug dosing strategies 
that are acceptable by the population under study and will achieve optimal drug exposure at 
the site of infection. Yet a significant challenge to designing dosing strategies is a lack of 
identified target concentrations protective against HIV. Regulatory agencies recommend 
optimizing dosing strategies for clinical trials with pharmacometric approaches [8] once the 
concentration-response relationship at the site of activity (e.g. mucosal tissues) is quantified. 
Therefore, a model system that can accurately predict in vivo correlations for 
chemoprophylaxis could significantly accelerate the chemoprevention field.
The human tissue explant system, which uses mucosal tissue from HIV negative donors 
exposed to HIV in an ex vivo culture system, is a preclinical tool to quantify 
chemoprevention efficacy but there is a paucity of data informing how this model relates to 
others used for antiretroviral drug screening and development. In this investigation, we 
explore the efficacy of maraviroc (MVC) and TFV using a human vaginal explant system 
coupled with a spliced RNA assay to detect the first rounds of HIV replication. We also 
determine the ability of both this explant model, and a typical cell monolayer system, to 
predict efficacy in a dose-challenge trial, whereby vaginal and cervical tissue is obtained by 
biopsy from healthy women volunteers given a single oral dose of MVC combined with 
TDF and challenged with HIV. Since cell models, explant tissues, and dose-challenge 
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studies are all being used in PrEP development, we sought to directly compare efficacy of 
tenofovir and maraviroc in these systems to better understand their predictive ability.
Methods
Additional details can be found in the Supplemental Methods.
Explant Tissue Procurement
Vaginal tissue samples were procured from surgical specimens and cadaver tissues. Surgical 
tissues were obtained through the UNC Tissue Procurement Facility under two UNC IRB 
approved protocols #09-0921 and #12-0368. Written informed consent was obtained from 
all participants. Cadaver tissues were obtained from the National Disease Research 
Interchange (Philadelphia, PA) and donors signed witnessed informed consent forms prior to 
death.
Spliced RNA Assay
Tissue explants were prepared and cultured similar to methods previously described [9, 10]. 
Explants were infected by incubation with 107 TCID50/well HIV-1JR-CSF/hPBMC for 3h, 
rinsed in medium, and transferred to gelfoam rafts.
Explants from 25 donors were used to quantify spliced viral RNA at 0, 24, 48, and 72h post-
inoculation. RNA was extracted using the Qiagen RNeasy Kit and converted to cDNA using 
SuperScript VILO cDNA Synthesis Kit (Life Technologies). A real-time PCR assay was 
designed to specifically detect mRNA copies from the D4-A7 splice site in the HIV-1JR-CSF 
genome. The spliced mRNA copy number per mg tissue was determined for each explant.
Viability, Immunohistochemistry and Immune Cell Quantification
Tissue viability in explants from 7 donors after 0, 4, and 7 days in culture was assessed 
quantitatively using the methylthiazolydiphenyl-tetrazolium bromide (MTT) (Sigma) assay 
similar to methods described by Greenhead et al [9]. Immunohistochemistry was performed 
on unexposed vaginal explants from 3 donors harvested at day 0, 4, and 7. Quantitation of 
CD3 and CD4-positive immune cells was performed by manual counting.
In explants from three donors, CCR5 mRNA was quantified at day 0, 4, and 7 with real-time 
PCR (Applied Biosystems 7300 Real Time PCR System, Life Technologies) using the 
Taqman Gene Expression Assay Hs00152917 (Life Technologies). RNA was extracted and 
converted to cDNA as above. Expression was normalized to ACTB expression (Assay ID 
Hs99999903) using the 2-ΔCt method [11].
In explants from three donors, concentrations of the endogenous nucleotides dATP and 
dCTP were measured at day 0, 1, and 2 by LC-MS/MS. These were targeted as they 
compete directly with TFVdp and FTCtp for anti-HIV activity. The analytical range for both 
dATP and dCTP was 0.020 - 20.0 ng/mL homogenate. Inter- and intra-day variability was 
<15%, and precision was within 10%.
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Concentration-Response Relationship in Vaginal Explant Tissue
Explants were pretreated in a 48-well tissue culture plate for 24h with 0.1-1000 ug/mL TFV 
(AptoChem) or 0.1-500 ug/mL MVC (Toronto Research Chemical). Explants from five 
donors were used to complete each dose response curve. Additional explants incubated in 
drug-free medium were used as donor-specific positive controls. Following the 24h pre-
incubation in TFV, one explant from each donor at each concentration was used to measure 
tenofovir diphosphate (TFVdp) tissue concentration [12]. Explants were then incubated with 
107TCID50/well HIV-1JR-CSF in the presence of the respective antiretroviral. At the end of 
the 3h incubation, one explant from each donor was harvested to measure background 
spliced viral RNA, and the remainder transferred to gelfoam rafts presoaked with drug-
containing medium in 12-well tissue culture plates. Explants were harvested daily for three 
days to measure spliced RNA as above.
TZM-bl Luciferase Assay
TZM-bl cells were pre-treated with dilutions of tenofovir ranging 10-4-103 ug/mL or 
maraviroc 10-5 -102 ug/mL for 24h prior to a 48h incubation with 103TCID50 HIV-1JR-CSF. 
Intracellular TFVdp was measured in TZMbl cells and normalized for cell weight (using a 
conversion factor of 42,208 cells/mg).
Antiretroviral Tissue Concentrations
The rate and extent of drug uptake into tissues from media was assessed in explants 
incubated in TFV or MVC for 3-72h. Drug elimination was assessed in additional explants 
by transferring to a drug-free system after achieving equilibrium. MVC, TFV, and TFVdp 
tissue concentrations were quantified as previously published [12, 13]. Samples with a peak 
below the assay's quantifiable limit were reported as 50% of the lower limit of quantification 
(LLOQ; determined by explant weight). Samples with no peak were reported as 10% of the 
LLOQ.
Dose Challenge Study
This study was approved by the UNC Biomedical Institutional Review Board (IRB# 
13-3940; ClinicalTrials.gov identifier NCT02039323) and conducted in accordance with 
industry standards. Eligible female subjects were enrolled in the study between days 7 and 
14 of their menstrual cycle. At enrollment, women were administered 600 mg TDF + 600 
mg MVC orally after an extended fast. PBMCs were collected prior to medication dosing to 
determine donor susceptibility to HIV infection ex vivo. Women returned 24 hours post-dose 
for 2 cervical and 2 vaginal biopsies, as previously described [12]. Subjects were monitored 
closely for adverse events. Follow-up safety visits were completed 7-14 days following 
biopsy.
Within 30 minutes of collection, biopsies were treated as described above for explant tissue. 
At 24 and 48h each, 1 vaginal and 1 cervical biopsy were weighed and harvested for spliced 
RNA. Tissues were considered uninfected if both the 24h and 48h biopsies were below the 
pre-determined threshold of 434 copies/mg tissue. This was based on the mean + 1 standard 
deviation of background RNA measured in 41 explants at the end of a 3h viral incubation.
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Data are presented as median (IQR) except where otherwise noted. Correlations between 
two variables were made using the Spearman Rank Correlation. Intradonor variability was 
described using coefficient of variation (CV%). EC50 (±standard error) concentrations were 
defined using the 4 parameter Emax model (see Supplemental Methods). Statistical analyses 
(Sigma Plot 11.0; (Systat Software Inc) were conducted two-sided with α=0.05.
Results
Early infection in explant cultures as measured by a spliced RNA assay
By quantifying a spliced viral RNA occurring in relative high abundance during active viral 
replication [14], a viral peak (defined as >50% increase from baseline) was observed in 
explants from 21/25 donors (84%) (Figure 1A). Of those infected, 90% had reached the 
detection threshold by 24h post-inoculation and 100% by 48h. The highest viral peak was 
observed in 57% of samples at 24h, 29% of samples at 48h, and 14% at 72h post-
inoculation, capturing the early round of viral replication. The viral growth curves of the 
remaining 4 donors never surpassed >50% baseline, suggesting these tissues did not become 
productively infected. In explants where conditions were tested in duplicate or triplicate 
(n=15 donors), the median intra-donor variability of spliced viral RNA at any harvesting 
time point was 23%.
Changes in architecture, immune cell composition, and viability over time require early 
infection measures
Over the first 7 days in culture, sloughing of the epithelial layer, along with a loss of 
histologic architecture, was noted. However, cellular viability, measured by the MTT assay, 
remained >90% from day 0-7 (Figure 1B). At day 4 of culture, CD3+ and CD4+ expression 
(by IHC) declined by 93% and 98% from baseline, respectively, and remained constant 
through day 7. CCR5 mRNA expression also declined 78% by day 4, and 93% by day 7. 
After 24h in culture, an 89% reduction in dATP concentrations and a 70% reduction in 
dCTP concentrations were observed.
Protection from HIV Infection Determined by Tenofovir-Diphosphate Concentration
TFV concentrations reached equilibrium between culture medium and tissue within 3h of 
incubation while the formation of intracellular TFVdp in tissues took 24-48h to achieve 
maximal concentrations (Figure 2). TFVdp concentrations correlated with TFV 
concentrations (N=31; r=0.51, p=0.004), and the median molar conversion of TFV to 
TFVdp was 0.3% (range 0.01-2.01%). However, at any given TFV concentration, TFVdp 
varied up to 100-fold between tissue donors. The formation of TFVdp was moderately 
correlated with tissue MTT viability (r=0.51, p=0.04).
An Emax model described the relationship between TFV concentration and HIV inhibition in 
vaginal explants. Inhibition of infection was determined by the % decrease in the weight 
normalized AUC24-72h of spliced RNA compared to ARV-free control tissue. The EC50 for 
TFV in this model was 97±8 ug/mL (Figure 3A). An Emax model utilizing intracellular 
TFVdp concentrations was also fit with an estimated EC50 of 716 ± 448 fmol/mg (Figure 
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3B). The model sum of squared errors were 9788 and 8895 for TFV and TFVdp 
respectively, indicating a better fit for TFVdp.
In TZM-bl cells, the measured TFVdp concentrations varied between experimental runs by 
2-fold. The predicted EC50 for TFV was 0.9 ug/mL ± 0.02 (Figure 3A) and for TFVdp was 
61± 18 fmol/mg (Figure 3B). These results reveal greater potency of TFVdp in this cell 
system, with the EC50 being approximately 10- (TFVdp) and 100- (TFV) fold lower than in 
vaginal explant tissue.
Maraviroc Efficacy in Vaginal Explants Wanes over Time
Following incubation with MVC, equilibrium was achieved within 6h. Despite consistent 
drug exposure, inhibition of HIV infection by MVC was not sustained over 3 days in 
culture. The concentration-response relationship was best defined by 24h data, with an EC50 
of 9.7 ± 65 ug/mL (Figure 3C). An EC50 of 0.006 ± 0.002 ug/mL was generated in TZM-bl 
cells, which was >1000-fold lower than in vaginal tissue.
Prediction of Efficacy from Oral Tenofovir Disoproxil Fumarate and Maraviroc
The expected efficacy from various oral doses of TDF combined with MVC was estimated 
by applying the Emax models from TZM-bl cells and vaginal tissues to TFV, TFVdp and 
MVC tissue concentrations obtained from a Phase I dose-ranging study [15, 16] Based on 
the respective Tmax of TFVdp and MVC in cervicovaginal tissue, 24h post-dose was chosen 
as the optimal sampling time. A single 200% dose of the combination of TDF+MVC 
showed the greatest likelihood of achieving protection (Supplemental Data). and was chosen 
for the dose-challenge study.
To simulate how long drug concentrations would be retained in biopsy samples obtained 
from clinical study participants, explant tissues were incubated in TFV or MVC until 
equilibrium was reached and then rinsed and placed in drug-free media. A rapid loss of drug 
from the tissue was observed with elimination half-lives of 3.3 and 2.8h for TFV and MVC 
respectively (Figure 2), indicating viral incubation needed to be performed quickly and 
inhibition of infection measured early. TFVdp displayed a monophasic elimination half-life 
of 20h, suggesting a larger window could be utilized if this compound was solely being 
investigated.
Study Participants and Adverse Events
Six pre-menopausal women were screened and enrolled between February –April 2014 
(Table 1). All adverse events reported were Grade 1. Medication-related events included 
nausea (n=2), dry mouth (n=2), increased bowel frequency (n=1), and light-headedness 
(n=1). All resolved prior to the follow-up visit.
Oral Maraviroc and Tenofovir Protection of Cervical and Vaginal Biopsies
To minimize the chance of negative tissue infection due to inherent biological processes, 
PBMCs were collected in subjects prior to drug administration and challenged with 
HIV-1JR-CSF. PBMCs were infected in 100% (6/6) of the volunteers. Results of the ex vivo 
HIV challenge are summarized in Figure 4. In 3/6 subjects, both vaginal and cervical tissues 
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were protected. One subject had mixed efficacy with cervical tissue protected but vaginal 
tissue infected. In the remaining 2 subjects, all tissues were infected by 48h.
Discussion
During drug development, the concentration-response relationship for both efficacy and 
toxicity is used to determine optimal dosing strategies for Phase III studies and regulatory 
approval [8]. This relationship is typically defined in Phase II investigations [8], whereby a 
select number of doses are evaluated for efficacy and toxicity in a limited patient population. 
However, defining these relationships is challenging for HIV prevention due to the large 
number of study subjects needed to meet the desired efficacy endpoint [17]. Three 
alternative approaches have been utilized to define effective concentration targets for HIV 
chemoprevention: cell lines [18-20], mucosal tissue explant systems [21-25], and “dose-
challenge” clinical studies [26, 27].
The mucosal tissue explant model is a clinical pharmacokinetic-pharmacodynamic 
surrogate, as it can measure protection in human tissue over a wide range of concentrations. 
Colorectal and ectocervical tissue have been utilized in evaluating the protective effect of 
UC781, tenofovir, dapivirine, and emtricitabine [21-25]. In this model, tissue is incubated 
with drugs of interest, challenged with HIVBaL, cultured over 10-21 days, and p24 
supernatant concentration used as a marker for infection. We sought to improve this model 
by 1) using a clinically relevant HIV strain, 2) developing a spliced RNA assay requiring 
only 3 days of culture, 3) measuring intracellular active metabolite concentrations of 
tenofovir to minimize variability in drug response, 4) comparing efficacy to a TZM-bl 
reporter cell model, and 5) evaluating its predictive potential to a dose-challenge study.
Data from human and macaque studies, and analysis of acutely HIV-infected subjects 
suggest the earliest infected cells in HIV mucosal transmission are CCR5+/CD4+ activated 
T cells [28-30]. Therefore, we chose HIV-1JR-CSF for our studies, a strain that is R5 and T-
cell tropic, but not macrophage tropic [31, 32]. We developed a real-time PCR assay which 
was able to detect infection within 3 days of exposure in 84% of explant donors; a rate 
consistent with other tissue models using longer incubation periods [33]. Our goal for rapid 
identification was to avoid any confounding by the early changes in tissue architecture, loss 
of CD3+, CD4+, and CCR5+ cells, and decline in endogenous nucleotides we and others 
have observed [21]. This assay measures the copy number of spliced HIV mRNA missing 
the RRE (encoding Vpr, Tat, Rev, or Nef). This D4-A7 splice occurs early in the HIV 
transcription process [34] with mRNA expressed in relative abundance in each actively 
infected cell [14], allowing for an amplified signal. This assay shortens culture periods, 
increases viral replication signal, decreases background noise, minimizes inter- and intra- 
donor variability in response [26, 27], and utilizes a single target to define infection [33, 35, 
36].
Following ex vivo incubation with TFV, we observed high inter-donor variability in the 
intracellular conversion to TFVdp, with maximum TFVdp concentrations occurring after 
24h of incubation. This observation may explain, in part, the tenofovir EC50 concentrations 
in other explant investigations which vary up to 10-fold between experiments (13, 16, 17). 
Nicol et al. Page 7






















Using TFVdp concentration improved the relationship between drug exposure and HIV 
protection.
For TFVdp, the EC50 of 700 fmol/mg generated in our vaginal explant model is similar to 
that generated in CAPRISA 004, where 52% efficacy was noted in highly adherent women, 
and TFV vaginal lumen concentrations >1000 ng/mL were more likely to be protective [37]. 
Previous pharmacokinetic investigations [38, 39] have demonstrated that this luminal 
concentration corresponds to ∼500 fmol/mg TFVdp in vaginal tissue. Although MVC was 
able to inhibit viral replication in a concentration-dependent manner, the inhibition was not 
seen after 24h despite constant drug exposure in the culture system. The reasons for the loss 
of efficacy are unclear, and further investigations into the dynamics of receptor binding in 
tissue are warranted. While there are no clinical trial data to compare, our explant model 
predicted a MVC EC90 of 3500 µg/mL, or 6.8mM, which is similar to the 5mM and 6mM 
vaginal gel formulations that provided 86% and 100% protection respectively in macaques 
[40] and humanized mice[41].
Compared to the EC50 identified in the TZM-bl cell monolayer, our explant model defined 
EC50 concentrations 10- and 1000-fold higher for TFVdp and MVC respectively. The TFV 
EC50 identified in our TZM-bl cell line of 0.9 ug/mL is comparable to a previous report in a 
similar HeLa derived cell line (37). Since TZM-bl and other cell lines are commonly used to 
assess antiretroviral efficacy [18-20], the discrepancy in effective concentrations should be 
considered when extrapolating between model systems and in vivo efficacy.
Combination therapy for PrEP is being pursued due to concerns over the development of 
drug resistance with monotherapy. A phase II safety and tolerability study comparing four 
oral antiretroviral regimens for prevention (including MVC in combination with TDF) is 
currently underway (NCT01505114). Therefore, we tested the combination of tenofovir and 
maraviroc in the TZM-bl cell model (Supplemental Data), which displayed an antiviral 
effect consistent with previously observed additive efficacy (36).
We also tested the efficacy of this combination in a dose-challenge model. This approach 
has been previously used to estimate colorectal tissue protection [26, 27], and is currently 
being investigated with vaginal and cervical tissue (NCT01505114, NCT01617096, 
NCT01363037). In this approach, HIV-negative volunteers are given oral or topical 
antiretrovirals, with mucosal tissue biopsies subsequently exposed to HIV. Based on the 
predicted efficacies from our cell and tissue Emax models, we chose to evaluate a double 
dose of TDF combined with MVC. This combination gave the greatest likelihood of 
protection at 24h and had the greatest discrepancy between tissue and cell model 
predictions. Using the assumption of additivity, the cell model predicted 99% protection 
while the explant model predicted 14% protection.
Overall efficacy in the dose challenge study was 50%: 36% higher than predicted by 
explants and 49% lower than predicted by cells. However, when correcting for a baseline 
infection rate of 84%, this regimen reduced infection by 34%: 20% higher than predicted by 
explants and 65% lower than predicted by a cell model. We postulate population differences 
may account for the under-prediction of the explant model. While the dose-challenge study 
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was conducted in young healthy pre-menopausal women, the explant results were generated 
with surgical tissue obtained from older women (80% were >50 yrs and post-menopausal). 
In addition to vaginal atrophy, changes in pH and microflora [42], and the loss of estradiol 
regulation on inflammatory mediators is associated with increased HIV replication in 
ectocervical explants from post-menopausal women [43]. Therefore it is possible that 
different target concentrations are required for protection in pre- versus post-menopausal 
women, and requires further exploration. All donors in the dose-challenge study 
demonstrated PBMC susceptibility to HIV-1JR-CSF, however further study is required to 
confirm that this is predictive of explant infectivity.
We believe our approach to the explant system has advantages both with the viral strain used 
and in the rapid detection of infection. However, there are two primary limitations. The first 
is they system representing a “worse-case scenario” for HIV infection. In this model, the 
epithelial layer no longer provides protection to immune cells, and the submucosa is directly 
exposed to virus. Although the system was intentionally designed to mimic compromised 
mucosal tissue, this model may overestimate the amount of antiretroviral required for 
protection of an intact epithelial surface. The second is the utilization of a high titer of virus. 
This titer was chosen to maximize the probability of an infectious event, and to identify 
ARV concentrations protective against all potential exposures. However, this approach may 
result in an overestimation of Emax. A more rigorous evaluation of titer and drug efficacy in 
this model is currently under study.
In conclusion, we have developed a novel mucosal tissue explant model that utilizes a 
clinically relevant viral strain and identifies protection from HIV infection within 72 hours. 
We also demonstrated that intracellular active metabolites of antiretrovirals should be 
measured directly in tissue to minimize variability in response and optimize interpretation. 
Our experiments sought to develop a model that could reliably predict clinical 
chemoprophylaxis success. While neither the cell model nor explant model accurately 
predicted efficacy observed in the dose-challenge clinical study, the explant model provided 
a closer estimate. Adjustment of covariates such as age of tissue donor and HIV inoculum 
size may increase the ability to mimic dose-challenge experiments and noninvasively 
determine pharmacokinetic-pharmacodynamic relationships between antiretroviral exposure 
in mucosal tissue and protection from HIV infection. We propose that an optimal drug 
development paradigm for PrEP include tissue explant studies performed to estimate 
effective mucosal concentrations prior to, or in parallel with, Phase I mucosal tissue 
pharmacokinetic studies. Biopsy-challenge studies can be used through Phase I and II to 
validate and further refine dosing. Overall, these investigations provide insight into 
relationships between preclinical models and provide a context for future studies of 
antiretroviral preventative efficacy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Nicol et al. Page 9























Wrote paper MN, AK; Critical review of manuscript CE, YF, JN, CS, EG, HP, KP, MC; Oversight of sample 
collection and clinical study protocols HP, KP, EG; Designed research MN, CE, JN, AK; Performed research MN, 
CE, CS; Analyzed data MN, CE, YF, JN, CS, AK. The authors would like to thank Michele Mathews and the UNC 
Translational Pathology Lab for immunhistochemical staining, Stephanie Mathews for assistance with 
interpretation and quantification of immunhistochemical staining, Dr. Ron Swanstrom and members of his 
laboratory for thoughtful discussion regarding the development of the model and the spliced RNA assay, Nicole 
White and Stephanie Malone for analytical analysis of drug concentrations in tissue samples, the UNC Lineberger 
Cancer Center Tissue Procurement Facility for assistance with tissue collection and processing, and the UNC 
Urogynecology Department for assistance with subject recruitment.
The following reagents were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: 
HIV-1JR-CSF from Dr. Irvin Chen, TZM-bl cells from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc., 
8E5/LAV cells from Dr. Thomas Folks.
Source of Funding: This work was supported by the National Institute of Allergy and Infectious Diseases [U01 
A1095031], the University of North Carolina at Chapel Hill Center for AIDS Research, an NIH funded program 
[P30 A150410], the American Foundation for Pharmaceutical Education, The National Institute of Diabetes and 
Digestive and Kidney Diseases [R37 DK049381], and National Institute of General Medical Sciences [T32 
GM086330].
References
1. UNAIDS. [Assessed November 12, 2013] UNAIDS report on the global AIDS epidemic. 2012. 
http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/
gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf
2. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an 
antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329:1168–
1174. [PubMed: 20643915] 
3. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual 
men and women. N Engl J Med. 2012; 367:399–410. [PubMed: 22784037] 
4. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men 
who have sex with men. N Engl J Med. 2010; 363:2587–2599. [PubMed: 21091279] 
5. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for 
heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367:423–434. [PubMed: 
22784038] 
6. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among 
African women. N Engl J Med. 2012; 367:411–422. [PubMed: 22784040] 
7. Marrazo, J.; Ramjee, G.; Nair, G., et al. Pre-exposure prophylaxis for HIV in Women: Daily Oral 
Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 
003); 20th Conference on Retroviruses and Opportunistic Infection; Atlanta, GA. 2013. Paper 
#26LB;
8. Bosinger SE, Li Q, Gordon SN, et al. Global genomic analysis reveals rapid control of a robust 
innate response in SIV-infected sooty mangabeys. J Clin Invest. 2009; 119:3556–3572. [PubMed: 
19959874] 
9. Greenhead P, Hayes P, Watts PS. Parameters of human immunodeficiency virus infection of human 
cervical tissue and inhibition by vaginal virucides. J Virol. 2000; 74:5577–5586. [PubMed: 
10823865] 
10. Grivel JC, Margolis L. Use of human tissue explants to study human infectious agents. Nat Protoc. 
2009; 4:256–269. [PubMed: 19197269] 
11. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat 
Protoc. 2008; 3:1101–1108. [PubMed: 18546601] 
12. Patterson KB, Prince HA, Kraft E, et al. Penetration of Tenofovir and Emtricitabine in Mucosal 
Tissues: Implications for Prevention of HIV-1 Transmission. Sci Transl Med. 2011; 3:112re114.
Nicol et al. Page 10






















13. Brown KC, Patterson KB, Malone SA, et al. Single and multiple dose pharmacokinetics of 
maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis. 2011; 
203:1484–1490. [PubMed: 21502084] 
14. Robert-Guroff M, Popovic M, Gartner S, et al. Structure and expression of tat-, rev-, and nef-
specific transcripts of human immunodeficiency virus type 1 in infected lymphocytes and 
macrophages. J Virol. 1990; 64:3391–3398. [PubMed: 2191150] 
15. Cottrell, ML.; Prince, HM.; Sykes, C., et al. Mucosal Tissues in Women Exhibit Different 
Concentrations of Endogenous Nucleotides and Intrecellular and Extracellular Antiretroviral 
(ARV) Concentrations: Implications for Preepxosure Prophylaxis (PrEP); 20th International AIDS 
Conference; Melbourne, Australia. 2014. 
16. Cottrell, ML.; Prince, HM.; Sykes, C., et al. Mucosal Tissue Pharmacokinetics of Maraviroc and 
Raltegravir in Women: Implications for Chemoprophylaxis. 15th International Workshop on 
Clinical Pharmacology of HIV and Hepatitis Therapy; 19-21 May 2014; Washington, D.C. 
Abstract O_08
17. National Research Council. Basic Design Features: Size, Duration, and Type of Trials, and Choice 
of Control Group. In: Lagakos, SW.; Gable, AR., editors. Methodological Challenges in 
Biomedical HIV Prevention Trials. Washington, DC: The National Academies Press; 2008. 
18. Khoury G, Ewart G, Luscombe C, et al. Antiviral efficacy of the novel compound BIT225 against 
HIV-1 release from human macrophages. Antimicrob Agents Chemother. 2010; 54:835–845. 
[PubMed: 19995924] 
19. Bradley J, Gill J, Bertelli F, et al. Development and automation of a 384-well cell fusion assay to 
identify inhibitors of CCR5/CD4-mediated HIV virus entry. J Biomol Screen. 2004; 9:516–524. 
[PubMed: 15452338] 
20. Uchida H, Maeda Y, Mitsuya H. HIV-1 protease does not play a critical role in the early stages of 
HIV-1 infection. Antiviral Res. 1997; 36:107–113. [PubMed: 9443667] 
21. Fletcher PS, Elliott J, Grivel JC, et al. Ex vivo culture of human colorectal tissue for the evaluation 
of candidate microbicides. Aids. 2006; 20:1237–1245. [PubMed: 16816551] 
22. Fletcher P, Harman S, Azijn H, et al. Inhibition of human immunodeficiency virus type 1 infection 
by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. 
Antimicrob Agents Chemother. 2009; 53:487–495. [PubMed: 19029331] 
23. Herrera C, Cranage M, McGowan I, et al. Colorectal microbicide design: triple combinations of 
reverse transcriptase inhibitors are optimal against HIV-1 in tissue explants. Aids. 2011; 25:1971–
1979. [PubMed: 21811139] 
24. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, et al. In vitro and ex vivo testing of tenofovir 
shows it is effective as an HIV-1 microbicide. PLoS One. 2010; 5:e9310. [PubMed: 20174579] 
25. Herrera C, Cranage M, McGowan I, Anton P, Shattock RJ. Reverse transcriptase inhibitors as 
potential colorectal microbicides. Antimicrob Agents Chemother. 2009; 53:1797–1807. [PubMed: 
19258271] 
26. Anton PA, Saunders T, Elliott J, et al. First phase 1 double-blind, placebo-controlled, randomized 
rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One. 2011; 
6:e23243. [PubMed: 21969851] 
27. Anton PA, Cranston RD, Kashuba A, et al. RMP-02/MTN-006: A phase 1 rectal safety, 
acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with 
oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses. 2012; 28:1412–1421. [PubMed: 
22943559] 
28. Nawaz F, Cicala C, Van Ryk D, et al. The genotype of early-transmitting HIV gp120s promotes 
alpha (4) beta(7)-reactivity, revealing alpha (4) beta(7) +/CD4+ T cells as key targets in mucosal 
transmission. PLoS Pathog. 2011; 7:e1001301. [PubMed: 21383973] 
29. Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. 
Annu Rev Med. 2011; 62:127–139. [PubMed: 21054171] 
30. Salazar-Gonzalez JF, Salazar MG, Keele BF, et al. Genetic identity, biological phenotype, and 
evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp 
Med. 2009; 206:1273–1289. [PubMed: 19487424] 
Nicol et al. Page 11






















31. Koyanagi Y, Miles S, Mitsuyasu RT, et al. Dual infection of the central nervous system by AIDS 
viruses with distinct cellular tropisms. Science. 1987; 236:819–822. [PubMed: 3646751] 
32. Cann AJ, Zack JA, Go AS, et al. Human immunodeficiency virus type 1 T-cell tropism is 
determined by events prior to provirus formation. J Virol. 1990; 64:4735–4742. [PubMed: 
2398528] 
33. Dezzutti CS, Uranker K, Bunge KE, et al. HIV-1 Infection of Female Genital Tract Tissue for use 
in Prevention Studie. J Acquir Immune Defic Syndr. 2013; 63:548–554. [PubMed: 23514957] 
34. Tazi J, Bakkour N, Marchand V, Ayadi L, et al. Alternative splicing: regulation of HIV-1 
multiplication as a target for therapeutic action. FEBS J. 2010; 277:867–876. [PubMed: 20082634] 
35. Richardson-Harman N, Lackman-Smith C, Fletcher PS, et al. Multisite comparison of anti-human 
immunodeficiency virus microbicide activity in explant assays using a novel endpoint analysis. J 
Clin Microbiol. 2009; 47:3530–3539. [PubMed: 19726602] 
36. Richardson-Harman N, Mauck C, McGowan I, et al. Dose-response relationship between tissue 
concentrations of UC781 and explant infectibility with HIV type 1 in the RMP-01 rectal safety 
study. AIDS Res Hum Retroviruses. 2012; 28:1422–1433. [PubMed: 22900504] 
37. Karim SS, Kashuba AD, Werner L, et al. Drug concentrations after topical and oral antiretroviral 
pre-exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011; 378:279–281. 
[PubMed: 21763939] 
38. Schwartz JL, Rountree W, Kashuba AD, et al. A multi-compartment, single and multiple dose 
pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One. 2011; 
6:e25974. [PubMed: 22039430] 
39. Kashuba, A.; Abdool Karim, SS.; Kraft, E., et al. Do systemic and genital tract tenofovir 
concentrations predict HIV seroconversion in the CAPRISA 004 tenofovir gel trial?. 18th 
International AIDS Conference; Vienna, Austria. 2010. Abstract TUSS0503
40. Veazey RS, Ketas TJ, Dufour J, et al. Protection of rhesus macaques from vaginal infection by 
vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis. 
2010; 202:739–44. [PubMed: 20629537] 
41. Neff CP, Kurisu T, Ndolot, Fox K, Akkina R. A topical microbicide gel formulation of CCR5 
antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS 
One. 2011; 6:e20209. [PubMed: 21673796] 
42. Farage MA, Maibach HI. Morphology and physiological changes of genital skin and mucosa. Curr 
Probl Dermatol. 2011; 40:9–19. [PubMed: 21325836] 
43. Rollenhagen C, Asin SN. Enhanced HIV-1 replication in ex vivo ectocervical tissues from post-
menopausal women correlates with increased inflammatory responses. Mucosal Immunol. 2011; 
4:671–681. [PubMed: 21881573] 
Nicol et al. Page 12






















Figure 1. Spliced RNA assay detects early HIV replication in vaginal explants
A) Spliced viral RNA and replication in explant tissue. Explant tissues were infected with 
107 TCID50/ well HIV-1 JR-SF. Baseline samples (Day 0) were harvested immediately 
following the end of the 3 hour viral incubation. Copy number of spliced RNA was 
determined using real-time PCR after reverse transcription and the fold change from 
baseline is reported (median/IQR). B) Rapid changes occur in explant tissue over time in 
culture. All values were normalized to an explant from the same tissue donor at Day 0 
(100%). Symbols represent the median values and error bars represent the Interquartile 
Range for MTT viability; error bars represent range for CCR5 gene expression, CD3/CD4 
IHC cell counts, and dATP/dCTP concentrations.
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Figure 2. Antiretrovirals are rapidly taken up by tissue and rapidly eliminated
Antiretroviral concentrations in tissue are reported as the percent initial concentration of the 
media tissues were incubated in assuming a tissue density of 1 g/mL. Symbols represent 
median values and errors represent range. Tissues incubated in MVC (2-4 explants per time 
point from a total of 10 donors) were rinsed at 24 hours (dashed arrow and transferred to a 
drug-free culture plate. Tissues incubated in TFV (2-6 explants per time point from total of 9 
donors) were rinsed at 48 hours (solid arrow). Inset: Formation and elimination of TFVdp 
from explant tissue. Explants from two vaginal donors were used to evaluate the rate of 
TFVdp formation over 48 hours of incubation in 100 ug/mL TFV. Explants from a separate 
three donors were used to evaluate the rate that TFVdp was eliminated from tissues. 
Explants were incubated in 100 ug/mL TFV for 24-48 hours, rinsed in culture media, and 
transferred to gelfoam raft. 48 hours represents the time the tissues were removed from TFV 
incubation (black arrow). Symbols represent median values and error bars represent range.
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Figure 3. Concentration response relationship of TFV, TFVdp, and MVC in Vaginal Explants 
and TZM-bl cells
Vaginal explants were incubated in TFV or MVC for 24 hours prior to a 3 hour viral 
exposure to 107 TCID50/ well HIV-1JR-CSF. TFVdp concentrations were measured at the 
time of viral exposure. TZM-bl cells were incubated in TFV or MVC for 24 hours prior to 
viral exposure. Symbols represent the raw data while the lines represent the predictions from 
the best fit Emax models. A) Percent inhibition versus the concentration of TFV in medium. 
B) Percent inhibition vs TFVdp measured in tissue explants. Percent inhibition in explant 
Nicol et al. Page 15






















tissues was determined by comparing the weight-normalized spliced RNA AUC24-72h of the 
ARV-treated tissues to the untreated positive controls. Percent inhibition in TZM-bl cells 
was determined by comparing the relative light units (RLU) to positive control (untreated 
cells) in a luciferase reporter assay. C) Percent inhibition in explant tissue vs MVC 
concentration in medium was determined by comparing the weight- normalized spliced 
RNA at 24 hours post-inoculation.
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Figure 4. Protection of mucosal biopsies from HIV following high dose of oral maraviroc and 
tenofovir
Two vaginal and two cervical biopsies were collected from all study participants 24 hours 
after a 600/600 mg dose of MVC/TDF and challenged within 30 minutes of collection with a 
three hour viral exposure to 107 TCID50/ well HIV-1JR-CSF. Spliced RNA was measured in 
tissues at one and two days post-inoculation. The dark dashed line represents the pre-
determined infection cutoff of 434 copies/mg. Open symbols represent vaginal tissues. 
Closed symbols represent cervical tissues. The same symbols represent tissues from the 
same subject.
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